MedTrace Logo

A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard Therapies

NCT00215696 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2011-05-13

No results posted yet for this study

Summary

The primary purpose of this study is to determine whether treatment with an experimental gene therapy (BIOBYPASS®) will reduce angina in study participants by stimulating the growth of new blood vessels. This will be measured by testing whether participants are able to exercise longer without experiencing angina after treatment, as compared to before treatment.

Additionally, this study will collect information about any side effects that might be related to the treatment with the experimental therapy.

Conditions

  • Moderate to Severe Angina Pectoris

Interventions

GENETIC

BioBypass®

Sponsors & Collaborators

  • GenVec

    lead INDUSTRY

Principal Investigators

  • Dr. Jens Kastrup · The Heart Center, University hospital Rigshospitalet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30

Countries

  • Denmark
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00215696 on ClinicalTrials.gov